← 프로그램 목록
ADCPhase 1Active
비교

DS-8201a (DP1)(Daiichi Sankyo / AstraZeneca)은 Advanced Solid Tumors 표적 ADC로, Advanced Solid Tumors 영역에서 개발·상용화 중입니다. 작용기전: targeting metabolic signaling. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 74.1% (ClinicalTrials.gov NCT03523585). 차별점: first-in-class antineoplastic agent for acute myeloid leukemia (AML), exhibits a distinctive pyrrolo[2,3-b]pyridine scaffold, and is s.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 8일 (6일 전)PK/독성 2026년 7월 8일 (6일 전)

Advanced Solid Tumors

Advanced Solid Tumors

Active

Technology

구조모아 · StructureMoa에서 구조 검색

ADC with potent antitumor activity

release

linker hydrolysis

retroviral pharmacology in the male genital tract: implications for HIV treatment and prev

humanized mice

first-in-class antineoplastic agent for acute myeloid leukemia (AML), exhibits a distinctive pyrrolo[2,3-b]pyridine scaffold, and is s

Mechanism of Action

targeting metabolic signaling

immune-mediated damage by enhancing renal clearance of cytokines

topoisomerase I inhibitor, has been challenged by its hydrophobicity, leading to aggregation, rapid clearance, and off-target toxicit

biomarkers in schizophrenia

resistance to trypsin degradation

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 64건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 3 · Phase 2
  • Status: Active, not recruiting · Completed · Recruiting
  • 주요 endpoint: Invasive Disease-free Survival (IDFS) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment · Disease-free Survival (DFS) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment · Overall Survival (OS) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment · Distant Recurrence-free Interval (DRFI) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment · Brain Metastases-free Interval (BMFI) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment
  • 등록된 결과: ORR 74.1%
  • 핵심: This study will compare DS 8201a to standard treatment. Participants must have HER2 breast cancer that has been treated…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

DS-8201a (DP1)은 어떤 치료제인가요?
DS-8201a (DP1)(Daiichi Sankyo / AstraZeneca)은 Advanced Solid Tumors 표적 ADC로, Advanced Solid Tumors 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
DS-8201a (DP1)의 임상 단계는?
DS-8201a (DP1)의 현재 단계는 Phase 1입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.